How do we calculate the economics of health? What are the negative and positive effects of health care being publicly funded? In this episode, Eline and Silvija discuss the importance of including health economical perspectives in clinical trials.
This article is from an episode of #Lørn, made in collaboration with LørnTech.
Title and company?
Associate Professor and Researcher at UiO.
Education and hobby?
Social economics, doctorate from UiO. Handball is a passion of mine. I have been coaching an amazing group of girls over the last eight years. Besides handball, I also enjoy flowers and gardening.
Who are you and how did you get into innovation and technology?
I studied social economics in the 90s, and that is when I took a course in health economics, which I really enjoyed. I liked it so much that I wrote my thesis on the subject. After a couple of years working for Statistics Norway I started on a PhD at UiO. To work at the intersection between health care and social economics is very meaningful. In addition to my research projects, I have been working together with clinicians for many years to include health economical analyses in clinical trials.
According to the Norwegian regulations for prioritization in health care, three criteria must be evaluated when we consider new treatments:
In recent years, I have been particularly concerned with the versatility of the methods that we use. Methods in health economics can be utilized beyond evaluating new treatments and drugs in the wake of clinical trials; as tools in innovation projects to discuss the potential for cost-effectiveness.
" Methods in health economics can be utilized ... as tools in innovation projects to discuss the potential for cost-effectiveness. "
What is the most important you do at work?
I would say it is two-fold. Research projects, as well as educating health economists who will be working in the pharmaceutical industry, management, consultancy and with research.
What is your focus in technology and innovation?
Precision medicine and to evaluate its development:
Why do you find it exciting?
Important decisions are based on knowledge and that we countinously develop our methods. It is important to recoqnize the act of turning down new technology as a decision made.
What do we do uniquely well in Norway related to all of this?
Increased use of Real-World Data (RWD) in combination with Randomized Controlled Trials (RCTs).
“All models are wrong, but some are useful” – George Box.
Recommended literature / videos about your professional field?
We are developing a novel pipeline, algorithm and computational tool, to assist clinicians in assigning the best therapy to individual patients by integrating in a novel and transparent way multiple type of data from patients